Welcome to our dedicated page for Leap Therapeutic SEC filings (Ticker: LPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive for Leap Therapeutics, Inc. under the historical ticker LPTX provides official documentation of the company’s evolution into Cypherpunk Technologies Inc. and its dual focus on oncology therapeutics and a Zcash-centered digital asset treasury strategy. Forms 8-K detail key events such as the October 2025 private placement led by Winklevoss Capital, adoption of the digital asset treasury strategy, and subsequent name change to Cypherpunk Technologies Inc., along with the planned shift to trading under the symbol CYPH on the Nasdaq Capital Market.
Regulatory reports describe capital markets transactions, including the issuance of common stock, pre-funded warrants, and common warrants, registration rights agreements, and a controlled equity offering sales agreement that allows at-the-market issuances of common stock. Other filings outline Nasdaq bid price deficiency notices, the grant of an additional compliance period, and the company’s consideration of a reverse stock split to address listing standards.
Filings also cover corporate governance and compensation, such as consulting and employment agreements with new digital asset–focused leadership, equity incentive awards in the form of restricted stock units, and board expansion and nomination rights for the lead investor. The definitive proxy statement for a special meeting explains proposals to increase authorized shares, authorize a reverse stock split range, adopt a new equity incentive plan, and approve additional share issuance under the private placement warrants.
For those analyzing the oncology side of the business, 8-Ks and related exhibits reference the wind-down of the DeFianCe clinical trial, reductions in research and development activities, and the exploration of strategic alternatives for sirexatamab and FL-501. On Stock Titan, these filings are paired with AI-powered summaries that help interpret complex agreements, capital structure changes, and disclosure language, while real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K, and proxy materials for the issuer formerly known as Leap Therapeutics are quickly accessible.
Cypherpunk Technologies Inc. (CYPH) reported a director equity grant. A Form 4 discloses an award of 74,700 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan. Each RSU converts into one share of common stock, par value $0.001, and the award was granted for no consideration.
The RSUs vested at issuance on the grant date and will be settled in common stock as soon as practicable after the earlier of (i) the fifth business day following the director’s departure from the Board or (ii) the first annual meeting of stockholders following the grant date. Following the reported transaction, the director holds 74,700 derivative securities on a direct ownership basis.
Cypherpunk Technologies (CYPH) reported a director equity grant on Form 4. On November 11, 2025, the director received 74,700 restricted stock units (RSUs) for no cash consideration under the 2022 Equity Incentive Plan. The RSUs vested at issuance.
Settlement into common stock will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the Board or the first annual stockholder meeting after the grant date.
Cypherpunk Technologies Inc. (CYPH) reported an insider equity grant. A director received 74,700 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan for $0 consideration, with each RSU settling 1-for-1 into common stock.
The RSUs vested at issuance. Settlement will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the board or the first annual meeting of stockholders following the grant date. Following the transaction, the filing lists 74,700 derivative securities held direct.
Cypherpunk Technologies Inc. (CYPH) filed a Form 4 reporting an equity grant to a director. On November 11, 2025, the reporting person was awarded 74,700 restricted stock units (RSUs) priced at $0 under the company’s 2022 Equity Incentive Plan.
The RSUs vested at issuance on the grant date, with settlement in common stock on a one-for-one basis. Settlement will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the Board or the first annual meeting of stockholders after the grant date, subject to applicable tax withholdings.
Cypherpunk Technologies Inc. (CYPH) reported a director equity award on Form 4. The reporting person received 74,700 restricted stock units (RSUs) on November 11, 2025 at an exercise price of $0, granted under the company’s 2022 Equity Incentive Plan.
The RSUs vested at issuance on the grant date and will be settled in common stock on the earlier of the fifth business day after the reporting person ceases to serve on the board or the first annual meeting of stockholders following the grant date. Following the transaction, the reporting person holds 74,700 derivative securities directly.
Cypherpunk Technologies Inc. (CYPH) reported a director equity grant on a Form 4. On November 11, 2025, the director received 74,700 restricted stock units (RSUs) awarded for $0 under the company’s 2016 Equity Incentive Plan.
The RSUs vested at issuance on the grant date and will be settled in common stock after the earlier of the fifth business day following the director’s service end or the first annual stockholders’ meeting after the grant. Following the transaction, the reporting person beneficially owned 74,700 derivative securities, held directly.
Cypherpunk Technologies Inc. (CYPH) reported a director’s equity grant on a Form 4. The director received 83,000 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan for $0 consideration.
The RSUs vested at issuance on the grant date. Settlement into common stock will occur as soon as practicable after the earlier of the fifth business day following the director’s service end or the first annual stockholder meeting following the grant date. The RSUs are shown as direct (D) ownership.
Cypherpunk Technologies Inc. (CYPH) reported insider equity awards. A director received 74,700 restricted stock units (RSUs) on November 11, 2025, recorded at $0 and held directly. These RSUs vested at issuance and will be settled in common stock after the earlier of the director leaving the Board or the first annual stockholders’ meeting following the grant.
Separately, 2,411,700 RSUs were awarded to CoinXit Ltd, shown as indirect beneficial ownership. Per the consulting agreement, these RSUs vest 12/36 on October 8, 2026 and 1/36 on the eighth day of each month thereafter, with settlement in common stock at the earliest of specified payroll dates tied to service cessation or semiannual settlement windows.
Cypherpunk Technologies Inc. filed an initial beneficial ownership statement for a director. The Form 3 indicates the reporting person serves as a director and, as of the event date 11/11/2025, reports no securities beneficially owned. The submission includes an Exhibit 24 Power of Attorney authorizing the filing. This is an administrative disclosure under Section 16 and does not reflect a transaction or change in the company’s capital.
Cypherpunk Technologies Inc. (NASDAQ: LPTX) established an at-the-market equity program, allowing sales of common stock of up to $200,000,000 through Cantor Fitzgerald & Co., which may act as sales agent or principal.
Sales may be made from time to time as “at the market offerings” under Rule 415. Cantor will receive a commission of up to 3.0% of gross proceeds. The company can suspend offers at any time, and either party may terminate the agreement with ten business days’ notice. Shares will be issued off the company’s effective Form S-3 shelf, with sales made pursuant to a prospectus supplement. The company also noted its corporate name change to Cypherpunk Technologies Inc., effective November 12, 2025.